Technology ID
TAB-3655
Mouse Model of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development
E-Numbers
E-243-2011-0
Lead Inventor
Erdos, Michael (NHGRI)
Co-Inventors
Collins, Francis (NHGRI)
Eriksson, Maria (Karolinska Institutet)
Varga, Renee (GeneDx, Inc)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Neurology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NHGRI
ICs
NHGRI
Children with Hutchinson-Gilford progeria syndrome (HGPS) suffer from acceleration of certain aging symptoms, mainly cardiovascular disease that generally leads to death from myocardial infarction and/or stroke. The cause of HGPS has been discovered to be a de novo point mutation in lamin A (LNMA) gene. NHGRI Scientist have generated a transgenic mouse model of HGPS. This mouse carries a bacterial artificial chromosome (BAC) with a De novo mutation 1824 C to T (G608G) mutated form of human LNMA. The transgenic animals lack external phenotype seen in human progeria but have vascular abnormalities that resemble the human phenotype. Specifically, the mice have progressive vascular smooth muscle cell loss in large arteries and replacement with proteoglycan and collagen, that is, they show progressive vascular calcification. This mouse model can be used to further understand the vascular pathology of progeria and to study potential progeria therapies.
Commercial Applications
- This mouse model can be used to further understand the vascular pathology of progeria and to study potential progeria therapies.
- Used to investigate symptoms of and treatments for other cardiovascular and aging disorders, especially those that involve atherosclerotic lesions and vascular calcification.
Competitive Advantages
Novel mouse model for a condition lacking efficacious treatment options.
Licensing Contact: